THERALINK TECHNOLOGIES, INC.
GOLDEN, CO · CIK 0001362703 · Biotech · Private
Novel cancer immunotherapy vaccine designed to stimulate immune system to attack cancer cells
oncbiomune.com →- Grants
- —
- No SBIR or STTR on record
- Sector median: 1
- Raised
- $2.6M
- 8 Form D · Dec 2022
- 46 months since last filing
- Contracts
- —
- No federal contracts on record
- Patents
- —
- No published records under this name
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓20092011201320152017201920212023
| Date | Event | Source | Amount |
|---|---|---|---|
| Private capital raised | Form D · SEC | $10,000 | |
| Private capital raised | Form D · SEC | $175,000 | |
| Private capital raised | Form D · SEC | $515,700 | |
| Private capital raised | Form D · SEC | $95,000 | |
| Private capital raised | Form D · SEC | $1,225,000 | |
| Private capital raised | Form D · SEC | $184,950 | |
| Private capital raised | Form D · SEC | $400,000 | |
| Private capital raised | Form D · SEC | $3,400,000 |
Form D · SEC
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 1603 | Maxwell Biosciences, Inc. | — | $11M |
| 1604 | Acer Therapeutics Inc. | — | $8.2M |
| 1605 | CeleCor Therapeutics, Inc. | — | $3.7M |
| 1606 | THERALINK TECHNOLOGIES, INC. | — | $2.6M |
| 1607 | Reglagene, LLC | — | $1.9M |
| 1608 | XenoTherapeutics Corp | — | $1.3M |
| 1609 | RIBO-THERAPEUTICS LLC | — | — |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Founders & Team
- Brian Barnett, M.D.Executive Officer
- Jeffrey BuschDirector
- Joseph CarusoneDirector · Executive Officer
- Thomas ChilcottExecutive Officer
- Thomas Chilcott, IIIExecutive Officer
- Robert ElliottDirector
- Robert Elliott, Jr.Director · Executive Officer
- Yvonne ForsDirector
- Jonathan HeadDirector · Executive Officer
- JONATHAN HEAD, PH.DDirector
- Robert HolcombDirector
- ROBERT HOLCOMBDirector
- Danica HolleyDirector
- Daniel HovermanDirector
- DANIEL HOVERMANDirector
- Andrew KucharchukDirector · Executive Officer
- ANDREW KUCHARCHUKExecutive Officer
- Charles RiceDirector
- Charles Rice, Jr.Director
- CHARLES RICE, JRDirector
- Mick RuxinDirector · Executive Officer
- Mick Ruxin, MDDirector · Executive Officer
- Matthew Schwartz, MDDirector
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.